Discover a world of educational opportunities to support your lifelong learning
Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP Fellowship
RACGP offer courses and events to further develop the knowledge you need to develop your GP career
2022 RACGP curriculum and syllabus
for Australian general practice
The Abuse and violence: working with our patients in general practice provides the best-available current evidence for GPs
Stay up-to-date with the latest information and resources on the COVID-19 vaccine rollout.
Download the Standards for general practice (5th edition) - a benchmark for quality care and risk management in Australian general practices
Coronavirus (COVID-19) resources for general practitioners
Advice and guidelines for GPs and practice teams to help protect general practice information systems
Video consultations can provide convenient and accessible healthcare delivery
Read all of the RACGP reports and submissions on various healthcare topics
Read all of the RACGP position statements on various healthcare topics
Join our RACGP Facebook groups
Guideline for the management of knee and hip osteoarthritis
We are unable to recommend either for or against electromagnetic/shortwave therapy for people with knee and/or hip osteoarthritis (OA).
Conditional (neutral) recommendation
Very low (hip)
Pulsed electromagnetic therapy, also known as pulsed shortwave therapy, is the application of pulsed electromagnetic fields to the body. As a pulsed mode of delivery, it does not produce a heating effect in the tissues, but is purported to have physiologically beneficial effects at the cellular level based on magnetic field effects. Traditionally, healthcare providers in clinical settings have administered pulsed electromagnetic therapy, but advances in technology have led to the increasing availability of small portable devices for self-application.
There is low-quality evidence that pulsed electromagnetic therapy significantly improves pain and function in people with knee OA (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document) by clinically relevant amounts. There is very low-quality evidence that pulsed electromagnetic therapy has no statistically significant effect on pain or function in people with hip OA (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document). Most studies involved clinician-delivered treatments, at high frequency of servicing, ranging from three to five times per week. A minority of studies used portable devices that individuals applied themselves at home, with treatment dosage ranging from two to 12 hours per day. Although the evidence suggests moderate effect sizes and a low risk of harms for pulsed electromagnetic fields in people with knee OA, the working group noted that current evidence is restricted to short-term (two to 10 weeks) follow-up only, so maintenance of a therapeutic effect remains uncertain. The available evidence suggests that three to five treatment sessions per week are required for benefits when this treatment is administered by clinicians. Given the large number of visits to a healthcare professional required for a treatment modality that is passive, the financial cost this may impose on an individual, and the evidence suggesting no benefit for hip OA, the working group felt that clinician-delivered pulsed electromagnetic therapy should not be offered to people with knee and/or hip OA. The working group noted some promising data from a limited number of small trials investigating portable devices, but felt further research is required regarding effectiveness, acceptability and adherence.
There is a low risk of adverse events, with no serious adverse events reported.
We suggest not offering electrotherapy modalities of shockwave, interferential or laser for people with knee and/or hip OA.
Conditional against recommendation
Very low (shockwave, interferential, laserhip)
Electrotherapy modalities (eg shockwave, interferential electrical current, laser therapy) are purported to induce physiologically beneficial effects on body tissues at a cellular level, including:
Shockwave therapy is typically delivered by clinicians, while portable units are available for interferential and laser modalities.
While very low-quality evidence suggests some possible benefits from shockwave and interferential current modalities on pain and function, these findings were limited trials (one for shockwave and two for interferential), with a limited sample size and serious or very serious risk of bias (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document). The working group also felt that the cost burden and requirement for frequent clinical visits (for shockwave) were additional factors contributing the recommendation to not offer these interventions.
Seven trials using laser therapy among people with knee OA suggest clinically meaningful benefits in short-term pain and function (up to three weeks); however, the quality of evidence is low to very low (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document). Despite these positive indications, the working group felt that it was inappropriate to recommend the use of laser for people with knee OA. This is because the evidence was derived from trials where clinicians were required to deliver the intervention two to three times per week (other than the trial by Stellian,94 where the intervention was self-administered), and the fact that the current evidence is restricted to short-term follow-up of three weeks. Furthermore, based on the model of service delivery used in the majority of trials, a considerable cost and time burden is likely to be placed on individuals. While there is no direct evidence available for the effects of these modalities in people with hip OA, the working group felt the modes of proposed physiologic action of the interventions would be transferable to the hip and the same concerns about cost, time, frequency of clinical visits and very short-term effects would similarly apply.
There is no evidence of harm across these modalities.
It may be appropriate to offer TENS that can be used at home for some people with knee and/or hip OA. Clinicians need to provide sufficient instructions on self-use, and consider individual accessibility and affordability.
Conditional for recommendation
TENS uses low voltage electric current delivered through electrodes fixed to the skin to affect peripheral nerve activity (neuromodulation) as a mechanism to modify nociception and the experience of pain. Portable TENS units are now widely available for people to use at home as a self-management strategy. Unlike other electrotherapy devices, portable TENS may be used as a continuous therapy by individuals to modulate pain, allowing them to engage in other activities while the unit is active.
Very low-quality evidence from four trials in people with knee OA suggests that TENS has a clinically meaningful effect on pain and function (Appendix 5 of the Guideline for the management of knee and hip osteoarthritis: Technical document). While no direct evidence is available from trials in people with hip OA, the working group felt that the mode of action with TENS could be transferable to the hip. Trials were limited to four weeks follow-up, so it remains uncertain whether treatment effects are maintained beyond this period. Accordingly, the working group felt it would be reasonable to offer TENS to individuals with knee and/or hip OA as a home-based, pain-modulating adjunct to active rehabilitation interventions.
No adverse events have been reported in the included trials. However, clinicians should provide information to people about how to use portable TENS units safely and minimise the risks of possible skin irritation.
Did you know you can now log your CPD with a click of a button?
Administrative-report.pdf (PDF 2.76 MB)
Algorithm-Holistic-assessment-diagnosis-and-management-of-knee-and-hip-osteoarthritis.pdf (PDF 0.05 MB)
Guideline-for-the-management-of-knee-and-hip-osteoarthritis-2nd-ed-Appendix-1.pdf (PDF 0.04 MB)
Guideline-for-the-management-of-knee-and-hip-osteoarthritis-2nd-ed-Appendix-2.pdf (PDF 0.05 MB)
Implementation-plan.pdf (PDF 1.79 MB)
Public-consultation-summary.pdf (PDF 0.29 MB)
Technical-document.pdf (PDF 5.79 MB)